ALFA Concalls
Every earnings call, live and summarised
Earnings calls
Every Blue Jet Healthcare earnings call we streamed: the live audio and our summary of what management said.
Record Q2 FY27 revenue of about ₹376 Cr (+28% QoQ), but gross margin fell 4ppt to 49% on West Asia raw-material costs. Management gave no numerical forward guidance; margin recovery depends on price hikes from Q3.
Record Q2 FY27 revenue of about ₹376 Cr (+28% QoQ), but gross margin fell 4ppt to 49% on West Asia raw-material costs. Management gave no numerical forward guidance; margin recovery depends on price hikes from Q3.
No numerical guidance given. Phase-one WISAC capex ~₹1,000 Cr, timing unspecified; Mahad unit on stream H2 FY27.
Blue Jet Healthcare reported Q1 FY27 revenue of ₹2,931mn, up 25% QoQ but down 17% YoY. Management is focusing on capacity expansion and forward integration into advanced contrast media intermediates.
Blue Jet Healthcare reported FY26 revenue of ₹947cr (-8% YoY) and PAT margin of 26%. Management highlights transition from investment to commercialization phase via significant Vizag greenfield expansion.
Blue Jet Healthcare reported FY26 revenue of ₹9,473 mn with 31% EBITDA margin. Strong growth in Contrast Media was offset by declines in Pharma Intermediates & API due to customer inventory normalization.
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.